ESC - European Society of Cardiology
ESC - European Society of Cardiology
08/29/2022 | Press release | Distributed by Public on 08/29/2022 08:46
Title: Trial supports full-dose anticoagulation to prevent blood clots in COVID-19 patients
Notes to editor
ESC Press Office
Tel: +33 (0) 7 8531 2036
Email: [email protected]
Follow us on Twitter @ESCardioNews
The hashtag for ESC Congress 2022 is #ESCCongress.
This press release accompanies both a presentation and an ESC press conference at ESC Congress 2022. It does not necessarily reflect the opinion of the European Society of Cardiology.
Funding: COVID-PACT was sponsored and funded by the TIMI Study Group, an academic research organisation of Brigham and Women's Hospital, an affiliate of Harvard Medical School. The TIMI Study Group receives research grant support, outside of this study, from multiple manufacturers of antithrombotic agents in cardiovascular disease.
Disclosures: Dr. Berg is a member of the TIMI Study Group, which has received institutional research grant support through Brigham and Women's Hospital from Abbott, Amgen, Anthos Therapeutics, ARCA Biopharma, Inc., AstraZeneca, Bayer HealthCare Pharmaceuticals, Inc., Daiichi-Sankyo, Eisai, Intarcia, Ionis Pharmaceuticals, Inc., Janssen Research and Development, LLC, MedImmune, Merck, Novartis, Pfizer, Quark Pharmaceuticals, Regeneron Pharmaceuticals, Inc., Roche, Siemens Healthcare Diagnostics, Inc., Softcell Medical Limited, The Medicines Company, Zora Biosciences. Dr. Berg is supported by Harvard Catalyst KL2/CMeRIT (NIH/NCATS grant UL 1TR002541) and has received consulting fees from AstraZeneca, Mobility Bio, Inc., and Youngene Therapeutics, honoraria from the Medical Education Speakers Network (MESN), and participates on clinical endpoint committees for studies sponsored by Kowa Pharmaceuticals.
References and notes
1COVID-PACT will be discussed during Hot Line Session 10 on Monday 29 August at 16:30 to 17:30 CEST in the Barcelona auditorium.
2Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. J Thromb Haemost. 2020;18:1559-1561.
3Piazza G, Campia U, Hurwitz S, et al. Registry of arterial and venous thromboembolic complications in patients with COVID-19. J Am Coll Cardiol. 2020;76:2060-2072.
4Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: Implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75:2950-2973.
5Berger JS, Kornblith LZ, Gong MN, et al. Effect of P2Y12 inhibitors on survival free of organ support among non-critically ill hospitalizedpPatients with COVID-19: A randomized clinical trial. JAMA. 2022;327:227-236.
6REMAP-CAP Writing Committee for the REMAP-CAP Investigators, Bradbury CA, Lawler PR, et al. Effect of antiplatelet therapy on survival and organ support-free days in critically ill patients with COVID-19: A randomized clinical trial. JAMA. 2022;327:1247-1259.
7RECOVERY Collaborative Group. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2022;399:143-151.
8ATTACC Investigators; ACTIV-4a Investigators; REMAP-CAP Investigators, et al. Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. N Engl J Med. 2021;385:790-802.
9REMAP-CAP Investigators; ACTIV-4a Investigators; ATTACC Investigators, et al. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. N Engl J Med. 2021;385:777-789.
10Lemos ACB, do Espirito Santo DA, Salvetti MC, et al. Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID). Thromb Res. 2020;196:359-366.
11Lopes RD, de Barros E Silva PGM, Furtado RHM, et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet. 2021;397:2253-2263.
12Spyropoulos AC, Goldin M, Giannis D, et al. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: The HEP-COVID randomized clinical trial. JAMA Intern Med. 2021;181:1612-1620.
13Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health. https://www.covid19treatmentguidelines.nih.gov/therapies/antithrombotic-therapy/?utm_source=site&utm_medium=home&utm_campaign=highlights.
14ASH guidelines on use of anticoagulation in patients with COVID-19. American Society of Hematology. https://www.hematology.org/education/clinicians/guidelines-and-quality-care/clinical-practice-guidelines/venous-thromboembolism-guidelines/ash-guidelines-on-use-of-anticoagulation-in-patients-with-covid-19.
About the European Society of Cardiology
The ESC brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people to live longer, healthier lives.
It is the world's largest gathering of cardiovascular professionals, disseminating ground-breaking science both onsite in Barcelona and online - from 26 to 29 August. Explore the scientific programme. More information is available from the ESC Press Office at [email protected].